Fabtech Technologies Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 16 Jul 2026 | Healthcare Services | Market Cap: ₹673 Cr
Fabtech Technologies targets a year-on-year growth of **30%** starting FY27 (Page 16). Profit After Tax (PAT) margins are expected to remain between 9% to 11%.
From Fabtech Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹147
Market Cap
₹673 Cr
P/E Ratio
13.8
How does Fabtech Technologies Ltd rank in Healthcare Services?
Compare Fabtech Technologies Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Fabtech Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹159 Cr, net profit ₹22 Cr.
Full financials →📊 Revenue & Sales Performance
- →Fabtech Technologies targets a year-on-year growth of **30%** starting FY27 (Page 16).
- →Execution of a **900 crore order book** is expected mostly in the next financial year, with about **30-40% spilling into Q1/Q2 FY28** (Page 16).
- →Average ticket size has increased to between **7 to 10 million dollars**, up from earlier 1.5 to 3 million dollars, boosting volumes and margins (Page 9, 22).
- →Increased presence and leveraging of markets in **UAE, Saudi Arabia, and eco-African regions** to drive volume growth and margin improvement (Page 22).
- →The company aims to capitalize on the growing medicinal independence movement in emerging markets, expanding its life sciences infrastructure footprint (Page 14).
- →Growth is supported by in-house design and manufacturing capabilities, and potential acquisitions further strengthening market position (Page 13).
- →Quarterly fluctuations expected, but annual growth guidance remains intact (Page 13).
📈 Profitability & Margins
- →Profit After Tax (PAT) margins are expected to remain between 9% to 11%.
- →There is flexibility to improve margins by rationalizing marketing and business development expenses, currently around ₹8.5 - 9 crores annually.
- →Operating profit margins are anticipated to benefit from increased ticket sizes, with orders moving from $1.5–3 million to $7–10 million.
- →Higher ticket sizes and expanded geographic leverage (UAE, Saudi, Eco-African region) are expected to enhance volumes and operating margins.
- →The company's focus on life sciences infrastructure and growing market presence in emerging geographies indicates sustained revenue growth.
- →Strong order book (₹900 crore) with execution expected to pick up by Q1 FY28 supports growth visibility.
- →Operating cash flow may remain negative during high growth phases due to working capital cycles but is expected to improve post-growth stabilization.
- →EPS growth likely aligns with PAT growth guided between ₹39–41 crores for FY26.
🏗️ Capital Expenditure Plans
- →Fabtech Technologies Limited has raised funds through an IPO to invest in strategic areas.
- →The company is planning acquisitions in Europe, UAE, and Saudi Arabia to strengthen local presence and conversion rates.
- →Investments are being made to own processes, IPs, and increase ticket sizes for bigger turnkey projects.
- →Fabtech is focusing on infrastructure projects including green energy options like solar (tied up with KP Greens).
- →They are preparing to expand beyond life sciences into sectors like data centers and semiconductors when the time is right.
- →The company is investing in building a strong design platform across process, air, and water domains with homegrown companies.
- →Capital is being allocated towards marketing and business development (8.5 to 9 crores annually) with some flexibility.
- →Preparing for expedited civil construction by clients to improve conversion and execution.
- →Exiting TSA Process Equipments Pvt Ltd (water solutions) in the current financial year as part of capital allocation strategy.
💰 Fundraising & Capital Structure
- →Fabtech Technologies Limited has raised funds through an IPO recently, with funds parked in Fixed Deposits earning interest (other income).
- →There is no explicit mention of imminent new fundraising through equity or debt in the transcript.
- →The company is focusing on executing existing orders and growing organically, including through acquisitions.
- →They have a "war chest for acquisitions," implying availability of funds for strategic purchases.
- →No specific new equity or debt raising plans were stated for the near future during the call.
📋 Order Book & Pipeline
- →As of January end, the order book stands at approximately INR 926 crore.
- →The order book is almost entirely export-focused, targeting international markets, primarily in emerging economies.
- →The company has a healthy pipeline of hot leads valued around USD 455 million.
- →Execution timeline for the current order book is expected to span 9 to 18 months, with efforts underway to expedite deliveries.
- →Major portion of the order book is expected to be executed in the next financial year, with roughly 30-40% spilling over into Q1 or Q2 of FY28.
- →The average ticket size of orders is increasing, currently around USD 7 million, with hot leads ranging between USD 7 to 10 million.
- →Order inflow has remained strong without cancellations or pricing pressures, signaling sustained demand.
Key Metrics
Continue your research
What Fabtech Tech.'s management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre Ltd (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnost.'s Q3 FY26 earnings call — and…
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare Ltd (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Frequently Asked Questions
What were Fabtech Technologies Ltd Q3 FY26 results?
Fabtech Technologies targets a year-on-year growth of **30%** starting FY27 (Page 16). Profit After Tax (PAT) margins are expected to remain between 9% to 11%.
What is Fabtech Technologies Ltd share price analysis?
Fabtech Technologies Ltd currently shows a neutral. The stock trades at a P/E of 13.8 with a market cap of ₹673 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fabtech Technologies Ltd planning capital expenditure?
Fabtech Technologies Limited has raised funds through an IPO to invest in strategic areas.
Keep Fabtech Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.